Clinical trial
A Randomized Phase II Multicenter, Open-Label Study Evaluating the Efficacy and Safety of IMAB362 in Combination With the EOX (Epirubicin, Oxaliplatin, Capecitabine) Regimen as First-Line Treatment of Patients With CLDN18.2-Positive Advanced Adenocarcinomas of the Stomach, the Esophagus or the Gastroesophageal Junction
NCT01630083 is registered in ClinicalTrials.gov with Astellas Pharma Global Development, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase II Multicenter, Open-Label Study Evaluating the Efficacy and Safety of IMAB362 in Combination With the EOX (Epirubicin, Oxaliplatin, Capecitabine) Regimen as First-Line Treatment of Patients With CLDN18.2-Positive Advanced Adenocarcinomas of the Stomach, the Esophagus or the Gastroesophageal Junction
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 19, 2012
- Completion date
- January 31, 2019
- Enrollment
- 252 (actual)
- Sites
- 48
Conditions
As the registry lists them; a condition with its own page is linked.
cldn18.2-positive adenocarcinoma of esophagus, cldn18.2-positive adenocarcinoma of the gastroesophageal junction, cldn18.2-positive gastric adenocarcinoma